ArticleAnimals : an open access journal from MDPI2026
Emergence of a Novel Porcine Reproductive and Respiratory Syndrome Virus 2 Strain Recombined from Two Modified Live Virus-like Strains and Its Pathogenicity for Piglets.
Article in Animals : an open access journal from MDPI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Porcine reproductive and respiratory syndrome (PRRS), caused by PRRS virus (PRRSV), poses a serious threat to the global swine industry. Although modified live virus (MLV) vaccines have been widely used in the field for PRRS prevention for decades, the safety and efficacy of these vaccines have long been controversial. Here, we report a rare recombination pattern in China: the emergence of a novel NADC30-like PRRSV strain recombined from two MLV-like strains. Genome comparative analysis reveals that the SCMS2025 isolate has a non-continuous 136-amino acid deletion in the NSP2 protein and shares the highest nucleotide identity of 87.6% with lineage 5 (L5) strains. Phylogenetic analysis showed that SCMS2025 was classified into L1 (NADC30-like) strains based on ORF5 genotyping, whereas it belonged to a single branch between L1 and L5 strains based on the complete genomic sequences. Strikingly, genomic recombination analysis revealed that the newly emerged PRRSV isolate likely resulted from complex recombination events between NADC30-like and two MLV-like strains (RespPRRS MLV and TJbd14-1 MLV-like strains). Furthermore, SCMS2025 infection caused transient overt clinical signs followed by rapid recovery, indicating that the novel PRRSV isolate is a low pathogenic strain. Notably, all SCMS2025-inoculated piglets remained seronegative for PRRSV-specific antibodies throughout the entire 14-day observation period, suggesting a delayed onset of the host humoral immune response. Our study provides evidence for the ongoing evolution of PRRSV through inter lineage recombination and highlights the urgent need for safe and effective vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.